Dickson, Mark A <br/><br/>
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.  [electronic resource] 

 -  JAMA oncology  Jul 2016 
 - 937-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>2374-2445 
<br/><br/><label>Standard No.: </label>10.1001/jamaoncol.2016.0264  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Cyclin-Dependent Kinase 4--antagonists & inhibitors<br/>Cyclin-Dependent Kinase 6--antagonists & inhibitors<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Liposarcoma--drug therapy<br/>Male<br/>Middle Aged<br/>Piperazines--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyridines--administration & dosage